{{medical}}
{{noteTA
|T=zh-tw:5號染色體長臂缺失症候群;zh-cn:5号染色体长臂缺失综合征;zh-hk:5號染色體長臂缺失综合症;
|1=zh-tw:症候群;zh-cn:综合征;zh-hk:综合症;
|G1=Chromosome 5q deletion syndrome
}}
{{Infobox disease 
 | Name            = 5號染色體長臂缺失症候群<br><small>({{lang|en|Chromosome 5q deletion syndrome}})</small>
 | Image           = 5q- syndrome Bone marrow.jpg 
 | Caption         =顯示出為"典型5q症候群"單核巨核細胞骨髓異常之顯微照片
 | DiseasesDB      = 34573 
 | ICD10           = 
 | ICD9            = 
 | ICDO            = {{ICDO|9986|3}} 
 | OMIM            = 153550 
 | MedlinePlus     = 
 | eMedicineSubj   = 
 | eMedicineTopic  = 
 | MeshID          = 
}}

'''5號染色體長臂缺失症候群'''（{{lang|en|Chromosome 5q deletion syndrome}}、5q症候群、5號長臂[[染色體單體症|染色體單體症]](monosomy)、5號染色體長臂缺失綜合症）是一種[[後天性疾病|後天性]]血液疾病，特徵是人類[[5號染色體|5號染色體]]「長臂」（q arm, band 5q31.1）的一部分缺失。這種染色體異常最常見伴隨著[[骨髓增生异常综合征|骨髓增生异常综合征]]（{{lang|en|MDS}}）而產生。 

它不與“5號長臂部分[[染色體三倍體症|染色體三倍體症]]（partial trisomy 5q）”等同，雖然這兩種病症的產生都在同一個系列裡可以觀察的到。<ref name="pmid4042393">{{cite journal |author=Lazjuk GI |title=Partial trisomy 5q and partial monosomy 5q within the same family |journal=Clin. Genet. |volume=28 |issue=2 |pages=122–9 |date=August 1985 |pmid=4042393 |doi= 10.1111/j.1399-0004.1985.tb00371.x|url= |author-separator=, |author2=Lurie IW |author3=Kirillova IA |display-authors=3 |last4=Zaletajev |first4=D. V. |last5=Gurevich |first5=D. B. |last6=Shved |first6=I. A. |last7=Ostrovskaya |first7=T. I.}}</ref>

此種症狀不能和[[猫叫综合症|猫叫综合症]]混為一談，因猫叫综合症是一種缺失第5號染色體「短臂」（p arm/petit）的症候群。
<!--
==Characteristics==
The 5q-syndrome is characterized by [[macrocytic_anemia|macrocytic anemia]] often [[thrombocytosis|thrombocytosis]], [[Pure_red_cell_aplasia|erythroblastopenia]], [[megakaryocyte_hyperplasia|megakaryocyte hyperplasia]] with [[nuclear_hypolobation|nuclear hypolobation]] and an isolated interstitial deletion of chromosome 5. The 5q- syndrome is found predominantly in females of advanced age.

==Causes==
An association with [[RPS14|RPS14]] has been identified.<ref name="pmid18202658">{{cite journal |author=Ebert BL |title=Identification of RPS14 as a 5q- syndrome gene by RNA interference screen |journal=Nature |volume=451 |issue=7176 |pages=335–9 |date=January 2008 |pmid=18202658 |doi=10.1038/nature06494 |url= |author-separator=, |author2=Pretz J |author3=Bosco J |display-authors=3 |last4=Chang |first4=Cindy Y. |last5=Tamayo |first5=Pablo |last6=Galili |first6=Naomi |last7=Raza |first7=Azra |last8=Root |first8=David E. |last9=Attar |first9=Eyal}}</ref>

Deletion of the [[mir-145|miR-145]] and [[miR-146|miR-146]] loci has been associated with elevated [[platelet|platelet]] count and megakaryocytic dysplasia associated with the 5q- syndrome.<ref name="pmid19898489">{{cite journal |author=Starczynowski DT |title=Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype |journal=Nature Medicine |volume=16 |issue=1 |pages=49–58 |date=January 2010 |pmid=19898489 |doi=10.1038/nm.2054 |url= |author-separator=, |author2=Kuchenbauer F |author3=Argiropoulos B |display-authors=3 |last4=Sung |first4=Sandy |last5=Morin |first5=Ryan |last6=Muranyi |first6=Andrew |last7=Hirst |first7=Martin |last8=Hogge |first8=Donna |last9=Marra |first9=Marco}}</ref>

==Histology==
This syndrome affects [[bone_marrow|bone marrow]] cells causing treatment-resistant [[anemia|anemia]] and [[myelodysplastic_syndrome|myelodysplastic syndrome]]s that may lead to [[acute_myelogenous_leukemia|acute myelogenous leukemia]]. Examination of the [[bone_marrow|bone marrow]] shows characteristic changes in the [[megakaryocytes|megakaryocytes]]. They are more numerous than usual, small and mononuclear. There may be accompanying erythroid hypoplasia in the bone marrow.<ref>{{OMIM|153550|5q- syndrome}}</ref>

==Treatment==
[[Lenalidomide|Lenalidomide]] is a new agent that is showing promise in treating 5q- syndrome.<ref name="pmid17021321">{{cite journal |author=List A |title=Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion |journal=N. Engl. J. Med. |volume=355 |issue=14 |pages=1456–65 |date=October 2006 |pmid=17021321 |doi=10.1056/NEJMoa061292 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17021321&promo=ONFLNS19 |author-separator=, |author2=Dewald G |author3=Bennett J |display-authors=3 |last4=Giagounidis |first4=Aristotle |last5=Raza |first5=Azra |last6=Feldman |first6=Eric |last7=Powell |first7=Bayard |last8=Greenberg |first8=Peter |last9=Thomas |first9=Deborah}}</ref> It is approved for a subset of cases.<ref name="pmid17893227">{{cite journal |author=Raza A |title=Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q |journal=Blood |volume=111 |issue=1 |pages=86–93 |date=January 2008 |pmid=17893227 |doi=10.1182/blood-2007-01-068833 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=17893227 |author-separator=, |author2=Reeves JA |author3=Feldman EJ |display-authors=3 |last4=Dewald |first4=G. W. |last5=Bennett |first5=J. M. |last6=Deeg |first6=H. J. |last7=Dreisbach |first7=L. |last8=Schiffer |first8=C. A. |last9=Stone |first9=R. M.}}</ref>

==Prognosis==
Most patients have a stable clinical course but are often transfusion dependent.
-->

==參見==
*[[後天性疾病|後天性疾病]](acquired disorder)
*[[先天性疾病|先天性疾病]](congenital disorder/congenital disease)

==註釋==
{{reflist}}

==外部連結==
*[http://rarediseases.info.nih.gov/gard/8723/disease/resources/1 5q- syndrome]{{Wayback|url=http://rarediseases.info.nih.gov/gard/8723/disease/resources/1 |date=20160331151748 }} at [[國立衛生研究院_(美國)|NIH's]] Office of [[罕见病|Rare Diseases]]

{{染色体异常}}
{{恶性髓系肿瘤}}

[[Category:骨髓腫瘤|Category:骨髓腫瘤]]
[[Category:罕見疾病|Category:罕見疾病]]
[[Category:後天性疾病|Category:後天性疾病]]
[[Category:常染色体单体性与缺失|Category:常染色体单体性与缺失]]